Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation
Blood Vessels, Thrombosis & Hemostasis · 2024-09 · 1 (3) · 100015
DOI: 10.1016/j.bvth.2024.100015 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2024-09. Verfasst von Samira Escopy und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDDK, NIGMS, National Institutes of Health.
Abstract (Originalsprache)
P-selectin is a membrane glycoprotein and a member of the selectin family of cell adhesion molecules. It is prestored in α-granules of platelets and Weibel-Palade bodies of endothelial cells and is rapidly expressed on their surfaces upon activation during the course of an inflammatory response. Although a critical component of the innate immune system, the interaction of P-selectin with its cognate ligand, P-selectin glycoprotein ligand 1 (PSGL-1) may mediate maladaptive events central to the pathophysiology of venous thromboembolism, cardiovascular disease, stroke, metabolic syndrome, and sickle cell disease, among other disorders. As a consequence, a growing understanding of the significance of P-selectin and PSGL-1 in human disease has motivated the design of inhibitors that target the P-selectin/PSGL-1 pathway. Herein, we review the development and evaluation of both biologic and small-molecule inhibitors, including preclinical studies and clinical trials that have evaluated therapeutic potential of these agents for a variety of diseases linked to dysregulated inflammatory and thrombotic responses.
Autor:innen und Institutionen
- Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
- Wyss Institute of Biologically Inspired Engineering, Harvard University, Boston, MA.
- Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA.
Förderung
- NIDDK
- NIGMS
- National Institutes of Health
- NHLBI
- Harvard Medical School
Zitieren
APA
Escopy, S., & Chaikof, E. L. (2024). Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation. Blood Vessels, Thrombosis & Hemostasis, 1(3), 100015. https://doi.org/10.1016/j.bvth.2024.100015
Vancouver
Escopy S, Chaikof EL. Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation. Blood Vessels, Thrombosis & Hemostasis. 2024;1(3):100015. doi:10.1016/j.bvth.2024.100015
BibTeX
@article{Escopy2024,
author = {Escopy, Samira and Chaikof, Elliot L},
title = {Targeting the P-selectin/PSGL-1 pathway: discovery of disease-modifying therapeutics for disorders of thromboinflammation},
journal = {Blood Vessels, Thrombosis & Hemostasis},
year = {2024},
volume = {1},
number = {3},
pages = {100015},
doi = {10.1016/j.bvth.2024.100015}
}
EUVIMED